Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010:2010:546826.
doi: 10.1155/2010/546826. Epub 2010 Aug 25.

Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications

Affiliations
Review

Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications

Claudio Campa et al. Mediators Inflamm. 2010.

Abstract

Choroidal neovascularization (CNV) is a common and severe complication in heterogeneous diseases affecting the posterior segment of the eye, the most frequent being represented by age-related macular degeneration. Although the term may suggest just a vascular pathological condition, CNV is more properly definable as an aberrant tissue invasion of endothelial and inflammatory cells, in which both angiogenesis and inflammation are involved. Experimental and clinical evidences show that vascular endothelial growth factor is a key signal in promoting angiogenesis. However, many other molecules, distinctive of the inflammatory response, act as neovascular activators in CNV. These include fibroblast growth factor, transforming growth factor, tumor necrosis factor, interleukins, and complement. This paper reviews the role of inflammatory mediators and angiogenic factors in the development of CNV, proposing pathogenetic assumptions of mutual interaction. As an extension of this concept, new therapeutic approaches geared to have an effect on both the vascular and the extravascular components of CNV are discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Fluorescein angiography of a classic choroidal neovascularization. (a) Early and (b) late angiograms: the lesion is characterized by a well demarcated area of early fluorescence with a progressive leakage of the dye to the subretinal space leading to blurring of the borders in the late phase of the exam.
Figure 2
Figure 2
Fluorescein angiography of a predominantly classic choroidal neovascularization. (a) Early and (b) late angiograms: the lesion has a mixture of angiographic features of the classic and occult type, with the classic component making up more than 50% of the entire neovascular complex.
Figure 3
Figure 3
Fluorescein angiography of a minimally classic choroidal neovascularization. (a) Early and (b) late angiograms: the lesion has a mixture of the angiographic features of the classic and occult type, with the classic component making up less than 50% of the entire neovascular complex.
Figure 4
Figure 4
Fluorescein angiography of an occult choroidal neovascularization. (a) Early and (b) late angiograms: the lesion appears within 1-2 minutes from the start of the exams and persists during the late phase; it is characterized by areas of irregular elevation of the retinal pigment epithelium that present stippled hyperfluorescence.

References

    1. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology. 1986;93(9):1169–1176. - PubMed
    1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. American Journal of Ophthalmology. 2004;137(3):486–495. - PubMed
    1. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1. Archives of Ophthalmology. 1999;117(10):1329–1345. - PubMed
    1. Arnold J, Barbezetto I, Birngruber R, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. American Journal of Ophthalmology. 2001;131(5):541–560. - PubMed
    1. Bressler NM. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25(2):119–134. - PubMed

MeSH terms

Substances